Corvus Pharmaceuticals, Inc.
$15.54
▲
1.8%
2026-04-21 06:15:00
www.corvuspharma.com
NGM: CRVS
Explore Corvus Pharmaceuticals, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$1.31 B
Current Price
$15.54
52W High / Low
$26.95 / $3.11
Stock P/E
—
Book Value
$0.82
Dividend Yield
—
ROCE
-69.6%
ROE
-32.6%
Face Value
—
EPS
$-0.53
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
37
Beta
0.97
Debt / Equity
1.53
Current Ratio
6.21
Quick Ratio
6.21
Forward P/E
-17.92
Price / Sales
—
Enterprise Value
$1.21 B
EV / EBITDA
-28.29
EV / Revenue
—
Rating
None
Target Price
$35.17
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Mineralys Therapeutics, Inc. | $30.07 | — | $2.52 B | — | -26.38% | -36.91% | $47.65 / $12.59 | $7.93 |
| 2. | Ensysce Biosciences, Inc. | $0.48 | — | $4.49 M | — | -355% | -3.25% | $4.85 / $0.31 | $0.7 |
| 3. | Allogene Therapeutics, Inc. | $2.42 | — | $582.63 M | — | -53.97% | -53.42% | $4.46 / $0.86 | $1.27 |
| 4. | Passage Bio, Inc. | $6.25 | — | $37.44 M | — | -110.08% | -1.14% | $20 / $5.12 | $5.89 |
| 5. | ORIC Pharmaceuticals, Inc. | $10.89 | — | $1.09 B | — | -36.81% | -41.27% | $14.93 / $4.52 | $3.9 |
| 6. | YD Bio Ltd | $5.31 | — | $382.42 M | — | -22.15% | -42.69% | $31 / $5.12 | $4.57 |
| 7. | Arcellx, Inc. | $115 | — | $6.73 B | — | -50.64% | -53.42% | $115.13 / $47.86 | $6.95 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M | 0 M | — |
| Operating Profit | -12.22 M | -10.57 M | -10.26 M | -9.92 M | -8.11 M | — |
| Net Profit | -12.32 M | -10.16 M | -8 M | 15.19 M | -12.11 M | — |
| EPS in Rs | -0.15 | -0.12 | -0.1 | 0.18 | -0.14 | — |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M |
| Operating Profit | -42.97 M | -27.55 M | -23.41 M | -32.56 M |
| Net Profit | -15.28 M | -62.29 M | -27.03 M | -41.31 M |
| EPS in Rs | -0.18 | -0.74 | -0.32 | -0.49 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 71.12 M | 68.91 M | 45.55 M | 68.24 M |
| Total Liabilities | 9.91 M | 36.34 M | 6.87 M | 12.12 M |
| Equity | 61.2 M | 32.57 M | 38.68 M | 56.12 M |
| Current Assets | 58.21 M | 54.41 M | 27.96 M | 43.66 M |
| Current Liabilities | 9.38 M | 35.4 M | 6.87 M | 10.75 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -32.8 M | -25.42 M | -23.93 M | -27.02 M |
| Investing CF | -7.8 M | -27.48 M | 15.54 M | -23.28 M |
| Financing CF | 36.43 M | 49.03 M | 7.86 M | 0 M |
| Free CF | -32.97 M | -25.42 M | -23.97 M | -27.29 M |
| Capex | -0.17 M | — | -0.03 M | -0.27 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | — | — | — | — |
| Earnings Growth % | -130.47% | 34.57% | — | — |
| Profit Margin % | — | — | — | — |
| Operating Margin % | — | — | — | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | — | — | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.